Ahlskog JE - Search Results

1

Slowing Parkinson's disease progression: recent dopamine agonist trials.

Ahlskog JE. Ahlskog JE. Neurology. 2003 Feb 11;60(3):381-9. doi: 10.1212/01.wnl.0000044047.58984.2f. Neurology. 2003. PMID: 12580184 Review.

2

Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide).

Ahlskog JE, Muenter MD, Bailey PA, Stevens PM. Ahlskog JE, et al. Arch Neurol. 1992 May;49(5):560-8. doi: 10.1001/archneur.1992.00530290152026. Arch Neurol. 1992. PMID: 1580821

3

Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients.

Ahlskog JE, Richelson E, Nelson A, Kelly PJ, Okazaki H, Tyce GM, van Heerden JA, Stoddard SL, Carmichael SW. Ahlskog JE, et al. Ann Neurol. 1991 Aug;30(2):185-91. doi: 10.1002/ana.410300210. Ann Neurol. 1991. PMID: 1654766

4

New concepts in the treatment of Parkinson's disease.

Ahlskog JE, Wilkinson JM. Ahlskog JE, et al. Am Fam Physician. 1990 Feb;41(2):574-84. Am Fam Physician. 1990. PMID: 1967895

5

Cerebrospinal fluid indices of blood-brain barrier permeability following adrenal-brain transplantation in patients with Parkinson's disease.

Ahlskog JE, Tyce GM, Kelly PJ, van Heerden JA, Stoddard SL, Carmichael SW. Ahlskog JE, et al. Exp Neurol. 1989 Aug;105(2):152-61. doi: 10.1016/0014-4886(89)90114-3. Exp Neurol. 1989. PMID: 2753115

6

PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent.

Muenter MD, Ahlskog JE, Bell G, McManis P. Muenter MD, et al. Among authors: ahlskog je. Neurology. 1988 Oct;38(10):1541-5. doi: 10.1212/wnl.38.10.1541. Neurology. 1988. PMID: 2901697

7

Guamanian neurodegenerative disease: investigation of the calcium metabolism/heavy metal hypothesis.

Ahlskog JE, Waring SC, Kurland LT, Petersen RC, Moyer TP, Harmsen WS, Maraganore DM, O'Brien PC, Esteban-Santillan C, Bush V. Ahlskog JE, et al. Neurology. 1995 Jul;45(7):1340-4. doi: 10.1212/wnl.45.7.1340. Neurology. 1995. PMID: 7617195

8

Hereditary late-onset chorea without significant dementia: genetic evidence for substantial phenotypic variation in Huntington's disease.

Britton JW, Uitti RJ, Ahlskog JE, Robinson RG, Kremer B, Hayden MR. Britton JW, et al. Among authors: ahlskog je. Neurology. 1995 Mar;45(3 Pt 1):443-7. doi: 10.1212/wnl.45.3.443. Neurology. 1995. PMID: 7898693 Free article.

9

Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline.

Ahlskog JE, Muenter MD, Maraganore DM, Matsumoto JY, Lieberman A, Wright KF, Wheeler K. Ahlskog JE, et al. Arch Neurol. 1994 Dec;51(12):1236-41. doi: 10.1001/archneur.1994.00540240080020. Arch Neurol. 1994. PMID: 7986180 Clinical Trial.

10

Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.

Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE, Matsumoto JY, Maraganore DM, Wright KF, Schoenfelder J. Lieberman A, et al. Among authors: ahlskog je. Neurology. 1993 Oct;43(10):1981-4. doi: 10.1212/wnl.43.10.1981. Neurology. 1993. PMID: 8105422 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

292 results

Search Page

Filters